PR Newswire All News ReleasesCodex · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 16:03:00·⟳ 抓取 16:03:26 +26s·⚡ 决策 08-27 16:20:32 +17m06s·61.4 天前
Capricor证券欺诈集体诉讼律所提醒投资者申请首席原告
本条是律所面向投资者的集体诉讼征集提醒,核心事实在7月FDA材料、7月顾问会和8月初多家律所诉讼公告中已被市场消化;没有新的法院/监管/公司事实足以支持新开空单。
📄 原文PR Newswire All News Releases↗ 原文
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES,…
不做 Capricor Therapeutics, Inc.(CAPR.US)
不做:本条是律师事务所重复征集首席原告的诉讼提醒,核心FDA与诉讼事实已在7月至8月初公开并重定价,缺少新裁定、SEC调查、正式拒批或新增损害量化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
CAPR的真正基本面冲击来自7月FDA briefing documents与顾问会负面投票,相关股价已在7月27日和7月30日大幅重定价;8月27日PR Newswire稿只是另一家律所重复提醒首席原告期限,新增信息主要是法律广告而非经营或监管实质进展,因此不做新交易。
消息传播链
- 公开转述称FDA briefing documents已提出统计分析计划变更等有效性证据问题,是后续诉讼的核心事实基础。市场反应:转述称CAPR.US于2026-07-27单日下跌64.5%。
- 公司8-K确认FDA顾问委员会以3票赞成、9票反对认为现有证据不支持Deramiocel治疗DMD心肌病有效性。市场反应:转述称CAPR.US在该消息后由7月29日收盘6.57美元跌至7月30日4.19美元。
- BFA Law已发布CAPR证券集体诉讼公告,披露同一首席原告截止日和类似诉讼指控。
- SBS Law再次提醒投资者参与CAPR证券欺诈集体诉讼,内容是律所广告性质的重复征集。
关键理由
- 诉讼提醒本身不改变Deramiocel获批概率、现金流或赔付责任的已知状态。
- 此前公开材料已显示FDA顾问会对有效性证据给出负面投票,诉讼指控也已在8月初同类公告中传播。
- 做空需要明确强新增负面催化,本条缺少新裁定、监管执法或公司承认。
主要风险
- 若随后出现法院认证、SEC调查、FDA正式拒批或公司披露更严重数据问题,CAPR.US可能重新具备事件驱动做空条件。
- 未能获取实时stock_tools报价,不能给出可执行入场价。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-13 · 影响 weakens
公司二季度更新称Deramiocel BLA仍在FDA审评中且现金约2.38亿美元,说明负面顾问会后尚未出现正式拒批。
检索:Capricor Deramiocel FDA advisory committee July 2026 BLA company update 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-08-04 · 影响 weakens
同一诉讼主题此前已公开,削弱8月27日律所提醒作为新增做空催化的有效性。
检索:CAPR securities class action lead plaintiff deadline September 28 2026 Deramiocel 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足且本条无新增事实,最终不升级为CAPR.US做空。
方向:律所集体诉讼提醒类公告通常是既有负面事件后的二次传播,方向偏负但新增交易价值弱。
涨幅量级:没有足够干净的同市场同机制先例可用于校准新一轮跌幅;本次更关键的是旧催化已大幅重定价。
形态:同类律师广告常见于股价大跌后,容易形成新闻噪音而非新增基本面冲击。
原文全文
展开原文 · 2,837 字
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: December 17, 2025 to July 26, 2026
DEADLINE: September 28, 2026
If you are a shareholder who suffered a loss, click here to participate.
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Capricor changed the statistical analysis plan used to analyze the clinical data related to Deramiocel despite the fact that the FDA had not agreed to changes from the pre-specified plan before the resubmission of its Biologics License Application ("BLA"). The Company faced a significant risk the FDA would not approve the BLA for Deramiocel based on a lack of sufficient evidence of effectiveness. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Capricor, investors suffered damages.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
SOURCE Schall, Brown & Schwartz LLP
LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: December 17, 2025 to July 26, 2026
DEADLINE: September 28, 2026
If you are a shareholder who suffered a loss, click here to participate.
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Capricor changed the statistical analysis plan used to analyze the clinical data related to Deramiocel despite the fact that the FDA had not agreed to changes from the pre-specified plan before the resubmission of its Biologics License Application ("BLA"). The Company faced a significant risk the FDA would not approve the BLA for Deramiocel based on a lack of sufficient evidence of effectiveness. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Capricor, investors suffered damages.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
SOURCE Schall, Brown & Schwartz LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。